A study at Saarland University has shown that a combination with active ingredients from Astrazeneca and Biontech/Pfizer appears to be the best combination.
AstraZeneca and Moderna have presented the interim results of their Phase 3 research. After a long wait, there are now three vaccines in sight instead of one.
The Belgian company Janssen is starting the final phase of their vaccine research in the United States, South Africa and South America. The Netherlands will also have its turn soon.